BioMarin Pharmaceutical Stock Price, News & Analysis (NASDAQ:BMRN)

$90.24 0.02 (0.02 %)
(As of 01/17/2018 03:18 PM ET)
Previous Close$90.22
Today's Range$90.09 - $92.00
52-Week Range$80.10 - $100.51
Volume1.43 million shs
Average Volume1.30 million shs
Market Capitalization$15.72 billion
P/E Ratio-108.72
Dividend YieldN/A
Beta1.81

About BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical logoBioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:BMRN
CUSIP09061G10
Phone+1-415-5066700

Debt

Debt-to-Equity Ratio0.41%
Current Ratio4.91%
Quick Ratio3.81%

Price-To-Earnings

Trailing P/E Ratio-108.722891566265
Forward P/E Ratio-141.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.12 billion
Price / Sales14.19
Cash FlowN/A
Price / CashN/A
Book Value$16.08 per share
Price / Book5.61

Profitability

Trailing EPS($0.83)
Net Income$-630,210,000.00
Net Margins-12.45%
Return on Equity-4.60%
Return on Assets-3.09%

Miscellaneous

Employees2,293
Outstanding Shares175,620,000

BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its earnings results on Thursday, October, 26th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.13) by $0.06. The biotechnology company had revenue of $334.18 million for the quarter, compared to analyst estimates of $347.38 million. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The firm's quarterly revenue was up 19.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.02 EPS. View BioMarin Pharmaceutical's Earnings History.

When will BioMarin Pharmaceutical make its next earnings announcement?

BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February, 22nd 2018. View Earnings Estimates for BioMarin Pharmaceutical.

Where is BioMarin Pharmaceutical's stock going? Where will BioMarin Pharmaceutical's stock price be in 2018?

21 equities research analysts have issued 1-year price objectives for BioMarin Pharmaceutical's stock. Their predictions range from $89.00 to $150.00. On average, they expect BioMarin Pharmaceutical's share price to reach $114.63 in the next twelve months. View Analyst Ratings for BioMarin Pharmaceutical.

What are Wall Street analysts saying about BioMarin Pharmaceutical stock?

Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:

  • 1. According to Zacks Investment Research, "BioMarin’s key orphan disease drugs – Vimizim and Kuvan – continue to do well, backed by strong underlying patient demand trends. BioMarin expects sustained growth in both the drugs. Brineura’s earlier-than-expected approval was also a huge boost for BioMarin. Its impressive rare-disease pipeline is also progressing well with approval for pegvaliase expected in 2018. The stock has slightly outperformed the industry in the past one year. However, BioMarin has suffered a few regulatory setbacks related to its pipeline candidates in the past. Further development setbacks can have a negative impact on the stock. Also, Naglazyme and Vimzin revenues vary on a quarterly basis primarily due to infrequent ordering patterns from some countries, mainly Brazil. Nonetheles, loss estimates have narrowed ahead of the company’s Q4 earnings result. BioMarin also has a positive record of earnings surprises in the recent quarters." (1/17/2018)
  • 2. Cowen Inc analysts commented, "New data include 52 wk follow-up on all patients at BMN270’s 6e13 vg/kg dose, and." (7/11/2017)
  • 3. Wedbush analysts commented, "The Wedbush View: While we see meaningful clinical, regulatory and commercial progress this year, we remain NEUTRAL on BMRN as we believe the stock is relatively expensive as it consistently trades at the top of peers." (5/8/2017)
  • 4. Jefferies Group LLC analysts commented, "Narrower 1Q GAAP net loss reflects higher revenue & lower OpEx (non- GAAP income of $35M). Next clinical update includes BMN 270 data at ISTH on 7/8-7/13/17." (5/5/2017)
  • 5. JPMorgan Chase & Co. analysts commented, "By Lotus Inventory Impacting Margins In Q1, all rev lines came in above expectations. While Med-Surg has been a consistent outperformer of late, CRM upside was another bright spot. The strong growth came against a tough comp. Headline margins were disappointing due to a spate of issues including the Lotus recall (not surprising), Fuse scope losses (somewhat more surprising) and litigation charges (also not surprising). The Lotus and Fuse charges are not expected to recur; excluding these, we view margins as fairly in-line. While the revenue raise positions BSX shares more favorably in our view, we continue to see the potential for risk around Lotus. While we expect strong data at EuroPCR, we wonder if mgmt’s FDA timelines are aggressive as we would think the FDA might ask for meaningful additional clinical work on the new delivery system following the EU recall. We remain positive on BSX’s underlying fundamentals but feel its current P/E valuation is appropriate until Lotus issues are entirely resolved or Symetis closes and sales ramp." (5/1/2017)

Who are some of BioMarin Pharmaceutical's key competitors?

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the folowing people:

  • Jean-Jacques Bienaime, Chairman of the Board, Chief Executive Officer (Age 63)
  • Daniel Keith Spiegelman, Chief Financial Officer, Executive Vice President (Age 58)
  • G. Eric Davis, Executive Vice President, General Counsel, Secretary (Age 46)
  • Jeff Robert Ajer, Executive Vice President, Chief Commercial Officer (Age 55)
  • Robert A. Baffi Ph.D., Executive Vice President - Technical Operations (Age 62)
  • Henry J. Fuchs M.D., Executive Vice President and Chief Medical Officer (Age 59)
  • Brian R. Mueller, Group Vice President, Corporate Controller, Chief Accounting Officer (Age 43)
  • Richard A. Meier, Lead Independent Director (Age 57)
  • Willard H. Dere M.D., Independent Director (Age 63)
  • Michael G. Grey, Independent Director

Who owns BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include National Pension Service (0.10%), Bank of Montreal Can (0.06%), Gateway Investment Advisers LLC (0.01%) and Creative Planning (0.00%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.

Who bought BioMarin Pharmaceutical stock? Who is buying BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock was purchased by a variety of institutional investors in the last quarter, including National Pension Service, Gateway Investment Advisers LLC, Bank of Montreal Can and Creative Planning. View Insider Buying and Selling for BioMarin Pharmaceutical.

How do I buy BioMarin Pharmaceutical stock?

Shares of BioMarin Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioMarin Pharmaceutical's stock price today?

One share of BioMarin Pharmaceutical stock can currently be purchased for approximately $90.24.

How big of a company is BioMarin Pharmaceutical?

BioMarin Pharmaceutical has a market capitalization of $15.72 billion and generates $1.12 billion in revenue each year. The biotechnology company earns $-630,210,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. BioMarin Pharmaceutical employs 2,293 workers across the globe.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 105 Digital Dr, NOVATO, CA 94949-8703, United States. The biotechnology company can be reached via phone at +1-415-5066700 or via email at [email protected]


MarketBeat Community Rating for BioMarin Pharmaceutical (BMRN)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  906 (Vote Outperform)
Underperform Votes:  427 (Vote Underperform)
Total Votes:  1,333
MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioMarin Pharmaceutical (NASDAQ:BMRN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.812.822.732.70
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
15 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
16 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $114.63$114.65$113.10$113.61
Price Target Upside: 25.21% upside29.50% upside28.33% upside30.62% upside

BioMarin Pharmaceutical (NASDAQ:BMRN) Consensus Price Target History

Price Target History for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ:BMRN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/22/2017WedbushReiterated RatingOutperform$110.00MediumView Rating Details
12/15/2017Goldman Sachs GroupUpgradeBuy -> Conviction-BuyHighView Rating Details
12/11/2017SunTrust BanksBoost Price TargetBuy$130.00HighView Rating Details
11/27/2017JPMorgan Chase & Co.Set Price TargetBuy$131.00MediumView Rating Details
10/27/2017BMO Capital MarketsBoost Price TargetOutperform$117.00 -> $119.00N/AView Rating Details
10/27/2017Stifel NicolausLower Price TargetBuy$107.00 -> $105.00N/AView Rating Details
10/19/2017Leerink SwannReiterated RatingOutperform$136.00 -> $142.00N/AView Rating Details
10/19/2017Credit Suisse GroupReiterated RatingOutperform$114.00 -> $124.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingOverweight$115.00 -> $117.00N/AView Rating Details
9/26/2017Jefferies GroupReiterated RatingBuy$116.00LowView Rating Details
9/21/2017Piper Jaffray CompaniesReiterated RatingBuy$113.00MediumView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform -> Sector Perform$93.00MediumView Rating Details
8/31/2017CitigroupInitiated CoverageBuy -> Buy$98.00MediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$100.00HighView Rating Details
8/9/2017Deutsche BankReiterated RatingBuy$118.00 -> $119.00LowView Rating Details
8/4/2017CowenReiterated RatingBuyLowView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$89.00HighView Rating Details
7/22/2017BarclaysReiterated RatingEqual Weight$105.00 -> $100.00LowView Rating Details
3/1/2017InstinetInitiated CoverageNeutral -> Neutral$93.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
2/10/2017GabelliReiterated RatingBuyN/AView Rating Details
1/9/2017Robert W. BairdSet Price TargetBuy$115.00N/AView Rating Details
7/28/2016William BlairSet Price TargetBuy$116.00N/AView Rating Details
6/20/2016OppenheimerReiterated RatingMarket Perform$99.00N/AView Rating Details
(Data available from 1/17/2016 forward)

Earnings

BioMarin Pharmaceutical (NASDAQ:BMRN) Earnings History and Estimates Chart

Earnings by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ BMRN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018($0.27)N/AView Earnings Details
10/26/2017Q3 2017($0.13)($0.07)$347.38 million$334.18 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.22)($0.21)$311.41 million$317.50 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.30)$0.03$292.58 million$303.70 millionViewListenView Earnings Details
2/23/2017Q416($0.38)($0.53)$296.54 million$300.00 millionViewN/AView Earnings Details
10/27/2016Q316($0.39)($0.13)$289.70 million$279.90 millionViewListenView Earnings Details
8/4/2016Q216($0.52)($2.61)$278.75 million$300.10 millionViewN/AView Earnings Details
4/28/2016Q116($0.85)($0.53)$240.21 million$236.70 millionViewListenView Earnings Details
2/25/2016Q415$0.67$0.39$224.14 million$227.90 millionViewListenView Earnings Details
10/29/2015Q315($0.65)($0.60)$216.32 million$208.90 millionViewListenView Earnings Details
8/3/2015Q215($0.53)($0.22)$218.16 million$250.50 millionViewN/AView Earnings Details
4/30/2015Q1($0.53)($0.25)$204.58 million$203.26 millionViewN/AView Earnings Details
2/25/2015Q414($0.59)($0.30)$189.01 million$230.90 millionViewN/AView Earnings Details
10/23/2014Q314($0.22)($0.16)$206.00 million$176.80 millionViewListenView Earnings Details
7/30/2014Q214($0.42)($0.19)$159.70 million$191.70 millionViewN/AView Earnings Details
5/1/2014Q1 2014($0.50)($0.27)$145.16 million$151.60 millionViewN/AView Earnings Details
2/26/2014Q413($0.35)($0.11)$146.07 million$146.90 millionViewN/AView Earnings Details
10/24/2013Q313($0.30)($0.38)$140.00 million$136.90 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.29)($0.16)$134.33 million$136.80 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.30)($0.31)$131.35 million$127.90 millionViewN/AView Earnings Details
2/21/2013Q4 2012($0.22)($0.43)$129.70 million$130.96 millionViewN/AView Earnings Details
10/25/2012($0.20)($0.04)ViewN/AView Earnings Details
8/1/2012($0.19)($0.27)ViewN/AView Earnings Details
4/26/2012($0.15)($0.21)ViewN/AView Earnings Details
2/16/2012($0.10)($0.23)ViewN/AView Earnings Details
10/27/2011($0.10)($0.16)ViewN/AView Earnings Details
7/28/2011($0.09)($0.05)ViewN/AView Earnings Details
4/28/2011($0.10)$0.14ViewN/AView Earnings Details
2/17/2011($0.02)($0.11)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.02)($0.03)ViewN/AView Earnings Details
8/2/2010Q2 2010$0.02($0.01)ViewN/AView Earnings Details
4/29/2010Q1 2010$0.01ViewN/AView Earnings Details
2/23/2010Q4 2009$0.05ViewN/AView Earnings Details
10/28/2009Q3 2009$0.06ViewN/AView Earnings Details
4/30/2009Q1 2009($0.12)($0.13)ViewN/AView Earnings Details
2/18/2009Q4 2008$0.24$0.24ViewN/AView Earnings Details
10/28/2008Q3 2008$0.03$0.01ViewN/AView Earnings Details
8/5/2008Q2 2008$0.02$0.04ViewN/AView Earnings Details
4/29/2008Q1 2008($0.04)$0.02ViewN/AView Earnings Details
2/26/2008Q4 2007$0.04$0.03ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

BioMarin Pharmaceutical (NASDAQ:BMRN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.28)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.17)($0.11)($0.14)
Q2 20182($0.07)($0.02)($0.05)
Q3 20183($0.11)($0.04)($0.08)
Q4 20182($0.05)$0.02($0.02)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for BioMarin Pharmaceutical (NASDAQ:BMRN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

BioMarin Pharmaceutical (NASDAQ BMRN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.85%
Institutional Ownership Percentage: 99.15%
Insider Trades by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)
Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ BMRN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/29/2018Jean Jacques BienaimeCEOSell10,000$89.61$896,100.00226,494View SEC Filing  
1/5/2018Jean Jacques BienaimeCEOSell10,000$90.32$903,200.00235,894View SEC Filing  
1/2/2018Henry J. FuchsInsiderSell15,000$89.23$1,338,450.00View SEC Filing  
1/2/2018V Bryan LawlisDirectorSell3,750$88.84$333,150.00View SEC Filing  
12/29/2017Jean Jacques BienaimeCEOSell20,000$89.75$1,795,000.00View SEC Filing  
12/14/2017Elaine J HeronDirectorSell800$88.90$71,120.0038,385View SEC Filing  
11/30/2017George Eric DavisEVPSell1,200$85.64$102,768.00View SEC Filing  
9/28/2017Robert BaffiEVPSell18,415$92.43$1,702,098.45129,083View SEC Filing  
9/22/2017Jeffrey Robert AjerEVPSell3,521$95.00$334,495.0049,299View SEC Filing  
9/15/2017Henry J FuchsInsiderSell15,000$90.50$1,357,500.00141,422View SEC Filing  
9/15/2017V Bryan LawlisDirectorSell3,750$91.26$342,225.0019,660View SEC Filing  
6/23/2017George Eric DavisEVPSell9,844$96.60$950,930.4093,425View SEC Filing  
6/22/2017Brian MuellerSVPSell2,671$100.00$267,100.0015,556View SEC Filing  
6/19/2017Henry J FuchsInsiderSell15,000$90.00$1,350,000.00141,422View SEC Filing  
6/16/2017V Bryan LawlisDirectorSell3,750$90.00$337,500.0019,660View SEC Filing  
6/7/2017Jeffrey Robert AjerEVPSell1,004$89.61$89,968.4447,944View SEC Filing  
6/5/2017George Eric DavisEVPSell9,471$91.04$862,239.8474,342View SEC Filing  
6/5/2017Jean Jacques BienaimeCEOSell10,000$90.13$901,300.00238,564View SEC Filing  
5/24/2017Jean Jacques BienaimeCEOSell5,000$88.38$441,900.00238,564View SEC Filing  
5/17/2017Jean Jacques BienaimeCEOSell5,000$91.73$458,650.00238,564View SEC Filing  
5/8/2017Brian MuellerSVPSell7,482$91.87$687,371.3418,350View SEC Filing  
5/8/2017Jean Jacques BienaimeCEOSell10,000$96.09$960,900.00238,496View SEC Filing  
5/5/2017George Eric DavisEVPSell2,500$100.34$250,850.0085,251View SEC Filing  
5/2/2017Jeffrey Robert AjerEVPSell302$96.74$29,215.4851,834View SEC Filing  
4/27/2017Jean Jacques BienaimeCEOSell5,000$95.72$478,600.00243,194View SEC Filing  
4/25/2017Jean Jacques BienaimeCEOSell5,000$94.00$470,000.00243,194View SEC Filing  
3/29/2017Jeffrey Robert AjerEVPSell3,890$89.15$346,793.5051,532View SEC Filing  
3/16/2017Daniel K SpiegelmanCFOSell1,989$91.96$182,908.4416,460View SEC Filing  
3/16/2017George Eric DavisEVPSell2,238$91.96$205,806.4875,967View SEC Filing  
3/16/2017Jean Jacques BienaimeCEOSell10,000$91.69$916,900.00211,364View SEC Filing  
3/10/2017Jean Jacques BienaimeCEOSell11,000$90.59$996,490.00212,364View SEC Filing  
3/7/2017Jeffrey Robert AjerEVPSell5,000$90.56$452,800.0046,510View SEC Filing  
3/6/2017Daniel K SpiegelmanCFOSell2,303$93.32$214,915.9620,761View SEC Filing  
3/6/2017George Eric DavisEVPSell1,498$93.32$139,793.3678,962View SEC Filing  
3/1/2017Daniel K SpiegelmanCFOSell35,000$94.07$3,292,450.0060,347View SEC Filing  
3/1/2017V Bryan LawlisDirectorSell7,500$95.00$712,500.0021,360View SEC Filing  
2/24/2017Henry J FuchsInsiderSell15,000$87.99$1,319,850.00128,442View SEC Filing  
1/26/2017Jean Jacques BienaimeCEOSell10,000$84.22$842,200.00175,682View SEC Filing  
1/11/2017Jean Jacques BienaimeCEOSell8,000$90.58$724,640.00174,682View SEC Filing  
1/9/2017Daniel K SpiegelmanCFOSell5,000$90.00$450,000.0018,100View SEC Filing  
1/9/2017Jean Jacques BienaimeCEOSell8,000$88.49$707,920.00174,682View SEC Filing  
12/30/2016Jean Jacques BienaimeCEOSell8,000$83.60$668,800.00174,682View SEC Filing  
11/22/2016Jean Jacques BienaimeCEOSell69,743$85.69$5,976,277.67View SEC Filing  
11/21/2016Jean Jacques BienaimeCEOSell69,744$87.56$6,106,784.64View SEC Filing  
11/8/2016Jean Jacques BienaimeCEOSell140,000$82.67$11,573,800.00393,368View SEC Filing  
11/7/2016Jean Jacques BienaimeCEOSell70,000$82.52$5,776,400.00393,368View SEC Filing  
10/28/2016Jean Jacques BienaimeCEOSell120,000$81.30$9,756,000.00383,368View SEC Filing  
10/17/2016Jean Jacques BienaimeCEOSell41,666$84.39$3,516,193.74365,034View SEC Filing  
10/14/2016Jean Jacques BienaimeCEOSell64,125$86.96$5,576,310.00378,184View SEC Filing  
9/29/2016Jean Jacques BienaimeCEOSell53,125$93.65$4,975,156.25431,709View SEC Filing  
9/27/2016Jeffrey Robert AjerEVPSell18,467$95.61$1,765,629.8741,342View SEC Filing  
9/16/2016Jean Jacques BienaimeCEOSell137,368$95.34$13,096,665.12421,161View SEC Filing  
8/26/2016Henry J FuchsEVPSell15,000$95.06$1,425,900.00128,878View SEC Filing  
8/16/2016Jean Jacques BienaimeCEOSell41,666$91.49$3,812,022.34420,250View SEC Filing  
8/1/2016Brian MuellerVPSell287$100.00$28,700.0014,260View SEC Filing  
8/1/2016Daniel K SpiegelmanCFOSell4,000$99.33$397,320.0042,944View SEC Filing  
8/1/2016George Eric DavisEVPSell2,167$100.00$216,700.0071,158View SEC Filing  
7/27/2016V Bryan LawlisDirectorSell1,100$95.39$104,929.0014,960View SEC Filing  
7/22/2016V Bryan LawlisDirectorSell6,400$95.01$608,064.0020,260View SEC Filing  
7/18/2016Jean Jacques BienaimeCEOSell41,666$92.72$3,863,271.52420,250View SEC Filing  
7/7/2016George Eric DavisEVPSell2,167$90.00$195,030.0072,836View SEC Filing  
6/20/2016V Bryan LawlisDirectorSell550$82.77$45,523.5013,860View SEC Filing  
6/16/2016Jean Jacques BienaimeCEOSell41,666$80.55$3,356,196.30420,250View SEC Filing  
6/6/2016Daniel K SpiegelmanCFOSell1,649$89.14$146,991.8646,944View SEC Filing  
5/31/2016Daniel K SpiegelmanCFOSell20,841$89.88$1,873,189.0871,235View SEC Filing  
5/26/2016Henry J FuchsEVPSell15,000$87.81$1,317,150.00130,914View SEC Filing  
5/23/2016Daniel K SpiegelmanCFOSell3,769$87.07$328,166.8358,644View SEC Filing  
5/18/2016Robert BaffiEVPSell5,000$87.05$435,250.00130,386View SEC Filing  
5/10/2016George Eric DavisEVPSell14,658$85.11$1,247,542.3891,894View SEC Filing  
5/5/2016Jean Jacques BienaimeCEOSell50,000$80.15$4,007,500.00390,156View SEC Filing  
5/3/2016Jeffrey Robert AjerEVPSell415$86.03$35,702.4563,487View SEC Filing  
5/2/2016Jean Jacques BienaimeCEOSell36,500$85.01$3,102,865.00395,635View SEC Filing  
3/14/2016George Eric DavisEVPSell1,996$86.21$172,075.1676,190View SEC Filing  
3/4/2016Jeffrey Robert AjerSVPSell1,255$88.42$110,967.1048,137View SEC Filing  
3/2/2016Daniel K SpiegelmanCFOSell4,623$86.12$398,132.7654,311View SEC Filing  
3/1/2016Jean Jacques BienaimeCEOSell10,000$84.28$842,800.00350,500View SEC Filing  
2/22/2016Michael G GreyDirectorSell7,500$80.00$600,000.0033,750View SEC Filing  
12/16/2015George Eric DavisSVPSell1,362$100.00$136,200.0066,156View SEC Filing  
11/30/2015Jean Jacques BienaimeCEOSell1,000$94.74$94,740.00228,754View SEC Filing  
11/16/2015Daniel K. SpiegelmanCFOSell20,000$104.30$2,086,000.0028,229View SEC Filing  
11/16/2015V Bryan LawlisDirectorSell8,550$106.90$913,995.0011,850View SEC Filing  
10/15/2015Jean Jacques BienaimeCEOSell1,000$108.24$108,240.00228,754View SEC Filing  
9/14/2015Jean Jacques BienaimeCEOSell1,000$131.43$131,430.00228,754View SEC Filing  
7/20/2015Jeffrey Robert AjerSVPSell3,000$150.00$450,000.00View SEC Filing  
7/7/2015Jean Jacques BienaimeCEOSell1,500$139.07$208,605.00View SEC Filing  
6/5/2015Daniel K SpiegelmanCFOSell1,649$122.30$201,672.70View SEC Filing  
6/5/2015Henry J FuchsEVPSell1,864$122.32$228,004.48View SEC Filing  
6/4/2015Jeffrey Robert AjerSVPSell1,362$122.35$166,640.70View SEC Filing  
6/1/2015Daniel K SpiegelmanCFOSell5,523$124.73$688,883.79View SEC Filing  
6/1/2015Jeffrey Robert AjerSVPSell377$123.76$46,657.52View SEC Filing  
5/29/2015Daniel K SpiegelmanCFOSell1,578$126.15$199,064.70View SEC Filing  
5/26/2015Jeffrey Robert AjerSVPSell1,625$126.55$205,643.75View SEC Filing  
5/18/2015Daniel K SpiegelmanCFOSell2,059$124.77$256,901.43View SEC Filing  
5/18/2015George Eric DavisSVPSell2,558$125.26$320,415.08View SEC Filing  
5/18/2015Henry J FuchsEVPSell1,864$124.78$232,589.92View SEC Filing  
5/13/2015Henry J FuchsEVPSell1,434$121.37$174,044.58View SEC Filing  
5/11/2015Henry J FuchsEVPSell2,869$121.64$348,985.16View SEC Filing  
3/17/2015Jean Jacques BienaimeCEOSell2,000$124.17$248,340.00View SEC Filing  
3/16/2015Henry J FuchsEVPSell41,315$123.57$5,105,294.55View SEC Filing  
3/16/2015Jean Jacques BienaimeCEOSell1,000$123.48$123,480.00View SEC Filing  
3/10/2015Jean Jacques BienaimeCEOSell21,021$112.39$2,362,550.19View SEC Filing  
3/9/2015Jean Jacques BienaimeCEOSell19,000$112.13$2,130,470.00View SEC Filing  
3/5/2015Jean Jacques BienaimeCEOSell10,000$113.70$1,137,000.00View SEC Filing  
3/5/2015Robert BaffiEVPSell14,051$116.37$1,635,114.87View SEC Filing  
3/4/2015Jean Jacques BienaimeCEOSell13,916$107.92$1,501,814.72View SEC Filing  
3/3/2015Jean Jacques BienaimeCEOSell5,000$107.42$537,100.00View SEC Filing  
3/2/2015Daniel K SpiegelmanCFOSell15,500$107.00$1,658,500.00View SEC Filing  
3/2/2015George Eric DavisSVPSell23,000$108.31$2,491,130.00View SEC Filing  
3/2/2015Jean Jacques BienaimeCEOSell5,000$108.44$542,200.00View SEC Filing  
1/9/2015Jean Jacques BienaimeCEOSell2,000$94.14$188,280.00View SEC Filing  
12/24/2014Jean Jacques BienaimeCEOSell5,000$88.73$443,650.00View SEC Filing  
12/10/2014Jean Jacques BienaimeCEOSell2,000$95.00$190,000.00View SEC Filing  
12/4/2014Alan LewisDirectorSell7,500$89.90$674,250.00View SEC Filing  
12/2/2014Brian MuellerVPSell11,950$90.91$1,086,374.50View SEC Filing  
11/25/2014George Eric DavisSVPSell20,000$89.75$1,795,000.00View SEC Filing  
11/25/2014Jean Jacques BienaimeCEOSell2,000$90.00$180,000.00View SEC Filing  
11/12/2014Jean Jacques BienaimeCEOSell1,000$81.51$81,510.00View SEC Filing  
11/10/2014Henry J FuchsEVPSell20,000$86.55$1,731,000.00View SEC Filing  
11/10/2014Jean Jacques BienaimeCEOSell4,000$87.00$348,000.00View SEC Filing  
11/3/2014Jean Jacques BienaimeCEOSell3,000$85.33$255,990.00View SEC Filing  
11/3/2014Jeffrey Robert AjerSVPSell47$83.54$3,926.38View SEC Filing  
10/30/2014Robert BaffiEVPSell75,425$81.34$6,135,069.50View SEC Filing  
10/24/2014Jean Jacques BienaimeCEOSell2,000$80.00$160,000.00View SEC Filing  
9/19/2014George Eric DavisSVPSell17,536$69.75$1,223,136.00View SEC Filing  
9/2/2014Daniel K SpiegelmanCFOSell16,000$69.83$1,117,280.00View SEC Filing  
8/20/2014Jean Jacques BienaimeCEOSell5,000$70.00$350,000.00View SEC Filing  
8/5/2014Henry J FuchsEVPSell10,000$65.00$650,000.00View SEC Filing  
8/1/2014Daniel K SpiegelmanCFOSell2,229$61.76$137,663.04View SEC Filing  
7/2/2014Daniel K SpiegelmanCFOSell2,229$64.00$142,656.00View SEC Filing  
6/4/2014Jean Jacques BienaimeCEOSell2,000$61.20$122,400.00View SEC Filing  
5/22/2014Jean Jacques BienaimeCEOSell1,000$56.88$56,880.00180,257View SEC Filing  
5/21/2014Jean Jacques BienaimeCEOSell1,545$56.19$86,813.55180,257View SEC Filing  
5/16/2014Henry FuchsEVPSell1,864$56.86$105,987.0460,950View SEC Filing  
5/16/2014Jeffrey Robert AjerSVPSell1,004$56.91$57,137.6420,980View SEC Filing  
5/16/2014V Bryan LawlisDirectorSell1,700$56.87$96,679.009,700View SEC Filing  
5/13/2014Henry FuchsEVPSell1,434$58.23$83,501.8264,850View SEC Filing  
5/9/2014Henry FuchsEVPSell3,479$57.91$201,468.8967,850View SEC Filing  
2/3/2014Henry FuchsEVPSell10,000$67.70$677,000.0042,350View SEC Filing  
12/24/2013Jean Jacques BienaimeCEOSell10,000$68.71$687,100.00View SEC Filing  
12/5/2013Jean Jacques BienaimeCEOSell5,000$69.70$348,500.00View SEC Filing  
10/16/2013Jean Jacques BienaimeCEOSell2,000$67.73$135,460.00View SEC Filing  
10/10/2013Jean Jacques BienaimeCEOSell3,000$66.76$200,280.00View SEC Filing  
9/19/2013Henry FuchsEVPSell10,000$80.19$801,900.0043,266View SEC Filing  
9/16/2013Jean Jacques BienaimeCEOSell2,000$73.08$146,160.00View SEC Filing  
9/9/2013Robert BaffiEVPSell20,000$73.00$1,460,000.00View SEC Filing  
9/5/2013Henry J FuchsEVPSell10,000$70.00$700,000.00View SEC Filing  
9/4/2013Daniel K SpiegelmanCFOSell9,000$69.00$621,000.00View SEC Filing  
8/15/2013Jean Jacques BienaimeCEOSell1,000$64.36$64,360.00View SEC Filing  
7/1/2013Daniel K SpiegelmanCFOSell4,066$59.78$243,065.48View SEC Filing  
7/1/2013Henry J FuchsEVPSell10,000$60.00$600,000.00View SEC Filing  
6/3/2013Henry J FuchsEVPSell1,098$58.32$64,035.36View SEC Filing  
5/23/2013Henry J FuchsEVPSell20,609$66.29$1,366,170.61View SEC Filing  
5/22/2013Mark WoodVPSell3,103$67.12$208,273.36View SEC Filing  
5/21/2013Jean Jacques BienaimeCEOSell2,000$64.14$128,280.00View SEC Filing  
5/16/2013Jean Jacques BienaimeCEOSell12,000$67.90$814,800.00View SEC Filing  
5/14/2013Brian MuellerVPSell4,947$70.35$348,021.45View SEC Filing  
5/14/2013George Eric DavisSVPSell20,000$70.34$1,406,800.00View SEC Filing  
5/14/2013Jean Jacques BienaimeCEOSell15,000$70.17$1,052,550.00View SEC Filing  
5/13/2013Jean Jacques BienaimeCEOSell15,800$68.77$1,086,566.00View SEC Filing  
5/13/2013Jeffrey Robert AjerSVPSell1,248$69.26$86,436.48View SEC Filing  
5/8/2013Jean Jacques BienaimeCEOSell4,000$65.87$263,480.00View SEC Filing  
5/2/2013Jean Jacques BienaimeCEOSell3,000$64.99$194,970.00View SEC Filing  
4/10/2013Robert BaffiEVPSell20,000$64.00$1,280,000.00View SEC Filing  
3/22/2013Mark WoodVPSell3,103$60.21$186,831.63View SEC Filing  
3/4/2013George Eric DavisSVPSell4,000$60.18$240,720.00View SEC Filing  
2/22/2013Mark WoodVPSell3,103$55.22$171,347.66View SEC Filing  
2/4/2013Jean Jacques BienaimeCEOSell2,000$55.77$111,540.00View SEC Filing  
12/27/2012Jean Jacques BienaimeCEOSell17,000$48.37$822,290.00View SEC Filing  
11/12/2012George Eric DavisSVPSell99,075$48.45$4,800,183.75View SEC Filing  
9/4/2012Henry J FuchsEVPSell5,000$37.76$188,800.00View SEC Filing  
8/22/2012Mark WoodVPSell2,665$37.93$101,083.45View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioMarin Pharmaceutical (NASDAQ BMRN) News Headlines

Source:
DateHeadline
Zacks: Analysts Expect BioMarin Pharmaceutical Inc. (BMRN) to Announce -$0.24 EPSZacks: Analysts Expect BioMarin Pharmaceutical Inc. (BMRN) to Announce -$0.24 EPS
www.americanbankingnews.com - January 16 at 11:42 AM
How Akcea Therapeutics’ Volanesorsen Performed in 3Q17How Akcea Therapeutics’ Volanesorsen Performed in 3Q17
finance.yahoo.com - January 11 at 10:09 AM
Insider Selling: BioMarin Pharmaceutical Inc. (BMRN) CEO Sells 10,000 Shares of StockInsider Selling: BioMarin Pharmaceutical Inc. (BMRN) CEO Sells 10,000 Shares of Stock
www.americanbankingnews.com - January 9 at 9:38 PM
How Was Incyte’s Revenue Stream in 3Q17?How Was Incyte’s Revenue Stream in 3Q17?
finance.yahoo.com - January 9 at 5:06 PM
Full interview with Shire CEO Flemming ØrnskovFull interview with Shire CEO Flemming Ørnskov
finance.yahoo.com - January 9 at 9:47 AM
BioMarin CEO on hemophilia treatment successBioMarin CEO on hemophilia treatment success
finance.yahoo.com - January 8 at 5:09 PM
How To Trade The JPMorgan Healthcare ConferenceHow To Trade The JPMorgan Healthcare Conference
finance.yahoo.com - January 8 at 5:09 PM
BioMarins chief calls hemophilia treatment results extremely encouragingBioMarin's chief calls hemophilia treatment results 'extremely encouraging'
finance.yahoo.com - January 8 at 5:09 PM
Surging Earnings Estimates Signal Good News for BioMarin Pharmaceutical (BMRN)Surging Earnings Estimates Signal Good News for BioMarin Pharmaceutical (BMRN)
finance.yahoo.com - January 5 at 9:55 AM
V Bryan Lawlis Sells 3,750 Shares of BioMarin Pharmaceutical Inc. (BMRN) StockV Bryan Lawlis Sells 3,750 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock
www.americanbankingnews.com - January 4 at 9:28 PM
BioMarin Pharmaceutical Inc. (BMRN) Insider Henry J. Fuchs Sells 15,000 SharesBioMarin Pharmaceutical Inc. (BMRN) Insider Henry J. Fuchs Sells 15,000 Shares
www.americanbankingnews.com - January 4 at 9:28 PM
BioMarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San FranciscoBioMarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco
finance.yahoo.com - January 3 at 9:05 AM
Insider Selling: BioMarin Pharmaceutical Inc. (BMRN) CEO Sells 20,000 Shares of StockInsider Selling: BioMarin Pharmaceutical Inc. (BMRN) CEO Sells 20,000 Shares of Stock
www.americanbankingnews.com - January 2 at 6:32 PM
BioMarin Pharmaceutical Inc. (BMRN) Receives Consensus Rating of "Buy" from BrokeragesBioMarin Pharmaceutical Inc. (BMRN) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 26 at 6:46 PM
BioMarin Pharmaceutical (BMRN) & Baxalta (BXLT) Head-To-Head SurveyBioMarin Pharmaceutical (BMRN) & Baxalta (BXLT) Head-To-Head Survey
www.americanbankingnews.com - December 26 at 1:34 PM
BioMarin Pharma (BMRN) Granted Anticipated Notification of PDUFA Extension for Pegvaliase Biologics License ApplicationBioMarin Pharma (BMRN) Granted Anticipated Notification of PDUFA Extension for Pegvaliase Biologics License Application
www.streetinsider.com - December 23 at 1:33 AM
Notable ETF Outflow Detected - XT, CTSH, MELI, BMRN - NasdaqNotable ETF Outflow Detected - XT, CTSH, MELI, BMRN - Nasdaq
www.nasdaq.com - December 22 at 8:25 PM
BioMarin Pharma (BMRN) Granted Anticipated Notification of PDUFA Extension for Pegvaliase Biologics License ... - StreetInsider.comBioMarin Pharma (BMRN) Granted Anticipated Notification of PDUFA Extension for Pegvaliase Biologics License ... - StreetInsider.com
www.streetinsider.com - December 22 at 8:25 PM
Wedbush Reaffirms "Outperform" Rating for BioMarin Pharmaceutical (BMRN)Wedbush Reaffirms "Outperform" Rating for BioMarin Pharmaceutical (BMRN)
www.americanbankingnews.com - December 22 at 12:18 PM
BioMarin Receives Anticipated Notification of PDUFA Extension for Pegvaliase Biologics License Application (BLA) to May 28, 2018BioMarin Receives Anticipated Notification of PDUFA Extension for Pegvaliase Biologics License Application (BLA) to May 28, 2018
finance.yahoo.com - December 22 at 9:58 AM
BioMarin's (BMRN) Gene Therapy Enters First Phase III StudyBioMarin's (BMRN) Gene Therapy Enters First Phase III Study
finance.yahoo.com - December 20 at 5:00 PM
BioMarins (BMRN) Gene Therapy Enters First Phase III StudyBioMarin's (BMRN) Gene Therapy Enters First Phase III Study
www.zacks.com - December 20 at 9:53 AM
BioMarin Doses First Patient in Global GENEr8-1 Phase 3 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia ABioMarin Doses First Patient in Global GENEr8-1 Phase 3 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
finance.yahoo.com - December 19 at 5:01 PM
BioMarin Pharmaceutical Inc. (BMRN) Director Sells $71,120.00 in StockBioMarin Pharmaceutical Inc. (BMRN) Director Sells $71,120.00 in Stock
www.americanbankingnews.com - December 18 at 11:38 PM
Ultragenyx sells rare drug voucher for $130 mln to NovartisUltragenyx sells rare drug voucher for $130 mln to Novartis
www.marketwatch.com - December 18 at 10:08 AM
FY2017 Earnings Forecast for BioMarin Pharmaceutical Inc. (BMRN) Issued By WedbushFY2017 Earnings Forecast for BioMarin Pharmaceutical Inc. (BMRN) Issued By Wedbush
www.americanbankingnews.com - December 18 at 3:28 AM
BioMarin Pharmaceutical (BMRN) Rating Increased to Sell at BidaskClubBioMarin Pharmaceutical (BMRN) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - December 16 at 9:56 AM
Research Analysts Offer Predictions for BioMarin Pharmaceutical Inc.s FY2021 Earnings (BMRN)Research Analysts Offer Predictions for BioMarin Pharmaceutical Inc.'s FY2021 Earnings (BMRN)
www.americanbankingnews.com - December 15 at 11:48 PM
FY2020 EPS Estimates for BioMarin Pharmaceutical Inc. (BMRN) Lifted by AnalystFY2020 EPS Estimates for BioMarin Pharmaceutical Inc. (BMRN) Lifted by Analyst
www.americanbankingnews.com - December 15 at 11:24 PM
BioMarin Pharmaceutical (BMRN) Raised to Conviction-Buy at Goldman Sachs GroupBioMarin Pharmaceutical (BMRN) Raised to Conviction-Buy at Goldman Sachs Group
www.americanbankingnews.com - December 15 at 9:04 AM
$347.40 Million in Sales Expected for BioMarin Pharmaceutical Inc. (BMRN) This Quarter$347.40 Million in Sales Expected for BioMarin Pharmaceutical Inc. (BMRN) This Quarter
www.americanbankingnews.com - December 15 at 6:44 AM
BioMarin Pharmaceutical (BMRN) Upgraded to "Outperform" at WedbushBioMarin Pharmaceutical (BMRN) Upgraded to "Outperform" at Wedbush
www.americanbankingnews.com - December 14 at 9:18 PM
BioMarin Pharmaceutical, Inc. – Value Analysis (NASDAQ:BMRN) : December 13, 2017BioMarin Pharmaceutical, Inc. – Value Analysis (NASDAQ:BMRN) : December 13, 2017
finance.yahoo.com - December 13 at 5:12 PM
BioMarin Pharmaceutical (BMRN) and Mediwound (MDWD) Head to Head ReviewBioMarin Pharmaceutical (BMRN) and Mediwound (MDWD) Head to Head Review
www.americanbankingnews.com - December 12 at 5:16 PM
How Did BioMarin Pharmaceuticals’ Drugs Perform in 3Q17?How Did BioMarin Pharmaceuticals’ Drugs Perform in 3Q17?
finance.yahoo.com - December 12 at 10:15 AM
SunTrust Banks Boosts BioMarin Pharmaceutical (BMRN) Price Target to $130.00SunTrust Banks Boosts BioMarin Pharmaceutical (BMRN) Price Target to $130.00
www.americanbankingnews.com - December 11 at 7:16 PM
NASDAQ Composite Index closes up 27.24 points for the week, rising for the 4th straight day - NasdaqNASDAQ Composite Index closes up 27.24 points for the week, rising for the 4th straight day - Nasdaq
www.nasdaq.com - December 11 at 5:14 PM
Why BioMarin Pharmaceutical Inc. Stock Is Surging Today - Investorplace.comWhy BioMarin Pharmaceutical Inc. Stock Is Surging Today - Investorplace.com
investorplace.com - December 11 at 5:14 PM
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $130 at SunTrust Robinson Humphrey Following ASH Update - StreetInsider.comBioMarin Pharmaceutical Inc. (BMRN) PT Raised to $130 at SunTrust Robinson Humphrey Following ASH Update - StreetInsider.com
www.streetinsider.com - December 11 at 5:14 PM
Why BioMarin Pharmaceutical Inc. Stock Is Surging TodayWhy BioMarin Pharmaceutical Inc. Stock Is Surging Today
investorplace.com - December 11 at 12:26 PM
Nasdaq 100 Movers: ORLY, BMRN - Presented by: The Aol. On NetworkNasdaq 100 Movers: ORLY, BMRN - Presented by: The Aol. On Network
www.nasdaq.com - December 11 at 10:34 AM
Five Winners - And One Loser - From Medicines Big Meeting About BloodFive Winners - And One Loser - From Medicine's Big Meeting About Blood
finance.yahoo.com - December 11 at 10:34 AM
BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia (ASH) MeetingBioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia (ASH) Meeting
finance.yahoo.com - December 11 at 10:34 AM
Spark Therapeutics shares slide more than 40% after hemophilia data disappointSpark Therapeutics shares slide more than 40% after hemophilia data disappoint
finance.yahoo.com - December 11 at 10:34 AM
After big IPO, biotech Denali Therapeutics climbs 20% in its first day of tradingAfter big IPO, biotech Denali Therapeutics climbs 20% in its first day of trading
www.bizjournals.com - December 8 at 4:57 PM
ETFs with exposure to BioMarin Pharmaceutical, Inc. : December 8, 2017ETFs with exposure to BioMarin Pharmaceutical, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 4:57 PM
BioMarin Pharma (BMRN) Announces Presentations at ASHBioMarin Pharma (BMRN) Announces Presentations at ASH
www.streetinsider.com - December 6 at 5:05 PM
BioMarin Announces Presentations at 59th American Society of Hematology Annual Meeting & ExpositionBioMarin Announces Presentations at 59th American Society of Hematology Annual Meeting & Exposition
finance.yahoo.com - December 6 at 9:59 AM
These 5 companies could disappear in 2018’s wave of M&AThese 5 companies could disappear in 2018’s wave of M&A
finance.yahoo.com - December 6 at 9:59 AM
Heres Why Sarepta Stock is Up More Than 70% in 6 MonthsHere's Why Sarepta Stock is Up More Than 70% in 6 Months
www.zacks.com - December 5 at 10:31 AM

SEC Filings

BioMarin Pharmaceutical (NASDAQ:BMRN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioMarin Pharmaceutical (NASDAQ:BMRN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioMarin Pharmaceutical (NASDAQ BMRN) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.